Double-Dose Gd-DTPA: Detectability of intraparenchymal brain metastasis

Nippon Acta Radiologica

Volumn 56, Issue 12, 1996, Pages 855-859

  Tatsuno, Satoshi ^a   Hata, Yuichi ^a   Tada, Shimpei ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Brain; Contrast material; Metastasis; MR imaging

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GADOLINIUM PENTETATE; ORGANOMETALLIC COMPOUND; PENTETIC ACID;

ADULT; AGED; ARTICLE; BRAIN TUMOR; FEMALE; HUMAN; IMAGE ENHANCEMENT; LUNG TUMOR; MALE; METASTASIS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PENTETIC ACID; PROSPECTIVE STUDIES;

EID: 0030265928     PISSN: 00480428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Sze G, Milano E, Johnson C, et al: Detection of brain metastases: comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. AJNR 11(4): 785-791, 1990
2. Davis PC, Hudgins PA, Peterman SB, et al: Diagnosis of cerebral metastases: double-dose delayed CT vs contrast-enhanced MR imaging. AJNR 12(2): 293-300, 1991
3. Bauer WM, Fenzl G, Vogl T, et al: Indications for the use of Gd-DTPA in MRI of the central nervous system. Experiences in patients with cerebral and spinal diseases. Invest Radiol Sep; 23(1): suppl 1 p. S281-286, 1988
4. Yuh WT, Engelken JD, Muhonen MG, et al: Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases. AJNR 13(1): 335-345, 1992
5. Yuh WT, Fisher DJ, Runge VM, et al: Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases. AJNR 151(6): 1037-1051, 1994
6. Yuh WT, Fisher DJ, Mayr-Yuh NA, et al: Review of the use of high-dose gadoteridol in the magnetic resonance evaluation of central nervous system tumors. Invest Radiol 27 (1): suppl 1 p S39-44, 1992
7. Yuh WT, Fisher DJ, Engelken JD, et al: MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 180(2): 485-491, 1991
8. Schubeus P, Schorner W, Haustein J, et al: Optimization of gadolinium-DTPA dose: an inter-individual study of patients with intracranial tumors. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 153 (1): 29-35, 1990
9. Yuh WT, Halloran JI, Mayr NA, et al: Dose of contrast material in the MR imaging evaluation of central nervous system tumors. J Magn Reson Imaging 4(3): 243-249, 1994
10. Haustein J, Laniado M, Niendorf HP, et al: Administration of gadopentetate dimeglumine in MR imaging of intracranial tumors: dosage and field strength. AJNR 13 (4): 1199-1206, 1992
11. Mayr NA, Yuh WT, Muhonen MG, et al: Cost-effectiveness of high-dose MR contrast studies in the evaluation of brain metastases. AJNR 15(6): 1053-1061, 1994
12. Hayman LA, Evans RA, Hinck VC: Delayed high iodine dose contrast computed tomography. Radiology 136: 677-684, 1980
13. Wessbecher FW, Maravilla KR, Dalley RW: Opitimizaing brain MR imaging protocols with Gadopentetate dimeglumine: enhancement of intracranial lesions on spin-density and T2-weighted images. AJNR 12: 675-679, 1991
14. Schorner W, Laliado M, Niendorf HP, et al: Time-dependent changes in image contrast in brain tumors after Gadolinium-DTPA. AJNR 7: 1013-1020, 1986
15. Haustein J, Laniado M, Niendorf HP, et al: Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology 186(3): 855-860, 1993
16. Niemi P, Kurki T, Lundbom N, et al: Magnetization transfer contrast in Gd-DTPA-enhanced imaging of brain tumors. Invest Radiol 1991 Nov 26(1): suppl 1 p. S248-249; discussion S253-254
17. Finelli D, Hurst GC, Cullapali RP, et al. Improved contrast of enhancing brain lesions on postgadolinium, T1-weighted spine-echo images with use of magnetization transfer. Radiology 190: 553-559, 1944